Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn's disease - PubMed
5 hours ago
- #microbiome
- #anti-TNFα therapy
- #Crohn's disease
- Colonic biopsy-associated microbial signatures can predict response to anti-TNFα therapy in Crohn's disease.
- The study involved 125 CD patients treated with anti-TNFα, vedolizumab, or ustekinumab, assessing pre-treatment gut microbiome via 16S rRNA sequencing.
- Anti-TNFα responders showed higher pre-treatment α-diversity in colonic biopsies, with 3.9% of β-diversity variation linked to response.
- Machine learning models, particularly for anti-TNFα colonic samples, achieved high predictive accuracy (AUC = 0.90).
- Specific bacteria like Mediterraneibacter gnavus were associated with non-response, while Blautia species correlated with response to anti-TNFα.
- In vitro tests showed M. gnavus reduced anti-TNFα-induced macrophage polarization more than B. luti.
- The findings suggest the colonic mucosal microbiome could serve as a predictive biomarker for anti-TNFα therapy response in CD.